LONDON--(BUSINESS WIRE)--Technavio has announced their latest pipeline analysis report on the psoriatic arthritis market. The report comprises an in-depth analysis of the pipeline molecules under investigation within the defined data collection period to treat psoriatic arthritis.
This report presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the coming years.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Save more with Technavio. Buy 2 reports and get the third for FREE: View all Technavio’s current offers
Psoriatic Arthritis - market overview
Psoriatic arthritis is an interminable joint pain leading to inflammation in people suffering from psoriasis, a type of skin disorder. Psoriasis can lead to scaly red and white skin patches. Psoriatic arthritis is commonly observed in large joints, especially those of the lower extremities, distal joints of the fingers and toes, and can affect the back and sacroiliac joints of the pelvis. It is mostly observed in individuals between the age group of 30 and 50, however, it can start at early ages too.
According to a senior analyst at Technavio for orthopedics and medical devices research, “Youngsters suffering from psoriatic arthritis are additionally in danger of developing uveitis, which is swelling of the middle layer of the eye. Around 15% of people with psoriasis can develop psoriatic joint inflammation. On rare occasions, the joint inflammation can show up before the skin issue.”
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Psoriatic arthritis – market segmentation
This market research report segments the psoriatic arthritis market based on therapies employed (monotherapy and unknown), therapeutic modalities (monoclonal antibody, small molecule and recombinant fusion proteins), and RoA (subcutaneous, IV, oral, and undisclosed).
The subcutaneous RoA is expected to account for around 38% of the market share followed by the oral and IV segments. In terms of therapeutic modalities, the monoclonal antibody segment accounted for 69% of the market share, followed by the small molecule segment.
|
Save big with Technavio this May! Find out what companies are venturing in to beat the heat this summer! Technavio indulges you with a massive 20% OFF on all
non-alcoholic
beverages reports for the entire month.
OR Technavio honors the achievements and efforts of Motherhood this Mother's Day by offering a whopping 30% OFF on all cosmetics and toiletry reports. Offer valid from 7th May for a limited period. |
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at media@technavio.com.
